Novavax applied to the European Union for approval of its vaccine.
Image: Reuters
The European Medicines Agency (EMA) announced on Wednesday that it has started testing and is expected to announce its decision within “a few weeks.” This vaccine is a so-called dead vaccine.
A generationThe fifth vaccine against Covid-19 may soon be approved in the European Union.The European Medicines Agency (EMA) announced on Wednesday that the US biotech company’s vaccine will be submitted for approval Novax Want to check faster. “If the data provided is reliable and complete enough to prove the effectiveness, safety and quality of the vaccine, a decision can be made within a few weeks.”
The vaccine is a so-called dead vaccine, which contains inactivated components of the new coronavirus used for immunization.This will be the first protein-based vaccine For Covid-19, this is allowed. In a pivotal Phase 3 study of 30,000 patients, the overall effectiveness of the vaccine was approximately 90%. However, as Novavax had to deal with production issues, the expected approval was delayed. The vaccine received emergency approval in the Philippines and Indonesia this month. The US approval application is scheduled to proceed by the end of the year. The EU has received as many as 200 million cans from the company.
inside European Union So far, four vaccines against Covid-19 have been approved, two of which are mRNA vaccines (Biontech and Moderna) and two are carrier vaccines (AstraZeneca and Johnson & Johnson).
